The shares of Colgate-Palmolive Company (NYSE:CL) has been pegged with a rating of Outperform by Evercore ISI in its latest research note that was published on January 11th, 2019. The research company has also assigned a $70 price target. Evercore ISI wasn’t the only research firm that published a report of Colgate-Palmolive Company, with other equities research analysts also giving their opinion on the stock. Goldman advised investors in its research note published on January 9th, 2019, to Buy the CL stock. The stock had earned Underweight rating from JP Morgan when it published its report on October 29th, 2018. The stock was given Hold rating by SunTrust in its report released on October 26th, 2018. Macquarie was of a view that CL is Neutral in its latest report on July 30th, 2018. Argus thinks that CL is worth Buy rating. This was contained in the firm’s report on May 25th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 14 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $63.58. The price of the stock the last time has raised by 14.42% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 66.07.
The shares of the company added by 0.98% during the trading session on Friday, reaching a low of $64.75 while ending the day at $65.69. During the trading session, a total of 3.04 million shares were traded which represents a 39.23% incline from the average session volume which is 5.00M shares. CL had ended its last session trading at 65.05. Colgate-Palmolive Company currently has a market cap of $57.07B, while its P/E ratio stands at 23.12, while its P/E earnings growth sits at 3.67, with a beta of 0.77. CL 52-week low price stands at $57.41 while its 52-week high price is $72.61.
The company in its last quarterly report recorded $0.74 earnings per share which is above the $0.73 predicted by most analysts. The Colgate-Palmolive Company generated $3,811.00 million in revenue during the last quarter, which is slightly higher than the $3,773.68 million predicted by analysts. In the second quarter last year, the firm recorded $0.72 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 2.7%. Colgate-Palmolive Company has the potential to record 2.84 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Longbow published a research note on February 5th, 2019 where it informed investors and clients that Gentex Corporation (NASDAQ:GNTX) is now rated as Neutral. Goldman also rated GNTX as Upgrade on January 9th, 2019, with its price target of $193 suggesting that GNTX could surge by 9.68% from its current share price. Even though the stock has been trading at $19.98/share, analysts expect it to surge higher by -1.05% to reach $21.89/share. It started the day trading at $20.005 and traded between $19.55 and $19.77 throughout the trading session.
A look at its technical shows that GNTX’s 50-day SMA is 21.26 while its 200-day SMA stands at 22.39. The stock has a high of $25.41 for the year while the low is $17.80. The company’s P/E ratio currently sits at 12.17, while the P/B ratio is 2.85. The company’s average trading volume currently stands at 2.00M shares, which means that the short-interest ratio is just 5.13 days. Over the past seven days, the company moved, with its shift of -5.86%. Looking further, the stock has dropped -8.34% over the past 90 days while it lost -17.14% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more GNTX shares, increasing its portfolio by +1.16% during the last quarter. This move now sees The Vanguard Group Inc purchasing 273,945 shares in the last quarter, thus it now holds 23,958,888 shares of GNTX, with a total valuation of $484,209,126. BlackRock Fund Advisors meanwhile sold more GNTX shares in the recently filed quarter, changing its stake to $436,485,920 worth of shares. Burgundy Asset Management Ltd followed the path by decreasing its GNTX portfolio by -4.87% in the quarter. This means that Burgundy Asset Management Ltd sold -523,097 shares in the last quarter and now controls 10,228,518 shares of the GNTX stock, with the valuation hitting $206,718,349.
Similarly, SSgA Funds Management Inc decreased its Gentex Corporation shares by -0.03% during the recently filed quarter. After selling -2,050 shares in the last quarter, the firm now controls 7,393,323 shares of Gentex Corporation which are valued at $149,419,058. In the same vein, Artisan Partners LP decreased its Gentex Corporation shares by during the most recent reported quarter. The firm sold -219,794 shares during the quarter which decreased its stakes to 5,978,748 shares and is now valued at $120,830,497. Following these latest developments, around 0.10% of Gentex Corporation stocks are owned by institutional investors and hedge funds.